Here's why you should take advantage. Here are two great examples in the biotech industry: Viking Therapeutics (NASDAQ: VKTX) and Exelixis (NASDAQ: EXEL). Viking Therapeutics, a mid-cap biotech ...

Investors in Exelixis Inc (Symbol: EXEL) saw new options become available this week, for the November 21st expiration. One of the key inputs that goes into the price an option buyer is willing to ...

RBC Capital analyst Gregory Renza maintained a Buy rating on Exelixis (EXEL – Research Report) on April 3 and set a price target of $40.00. The company’s shares closed yesterday at $34.57.